TSG-p53® - Models p53n4 and p53n5 Related Publications

Bielas JH, Heddle JA. (2003) Elevated mutagenesis and decreased DNA repair at a transgene are associated with proliferation but not apoptosis in p53-deficient cells. Proc Natl Acad Sci USA. 100(22):12853-8.

Ferguson DO, Sekiguchi JM, Chang S, Frank KM, Gao Y, DePinho RA, Alt FW. (2000) The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. Proc Natl Acad Sci USA. 97(12):6630-3.

Horn TL, Cwik MJ, Morrissey RL, Kapetanovic I, Crowell JA, Booth TD, McCormick DL. (2007) Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice. Food Chem Toxicol. 45(1):55-63.

Johansson FK, Brodd J, Eklöf C, Ferletta M, Hesselager G, Tiger CF, Uhrbom L, Westermark B. (2004) Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci USA. 101(31):11334-7.

Pritchard JB, French JE, Davis BJ, Haseman JK. (2003) The role of transgenic mouse models in carcinogen identification. Environ Health Perspect. 111(4):444-54.

Toledo F, Liu CW, Lee CJ, Wahl GM. (2006) RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses. Nucleic Acids Res. 34(13):e92.